The present invention relates to an organic mixture and an application thereof in organic electronic devices. The organic mixture comprises a spirofluorene organic compound containing a fused heterocyclic ring and an aromatic fused heterocyclic organic compound containing an electron-donating group. A combination of the two materials may be used as a host material of a phosphorescent organic light-emitting diode (OLED), which may use the energy of excitons and balance the charge transport to the greatest extent and which may effectively reduce the concentration of excitons and the operating voltage of a corresponding device, thereby effectively improving the efficiency and service life of the related electronic device in order to provide an effective solution for improving the overall performance of an organic electronic device.

The present invention provides compounds and methods for treating MKP-5 modulated disease. In certain embodiments, the MKP-5 modulated disease is a fibrotic disease.

Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

##STR00001##

The present invention addresses the issue of providing: a novel squarylium compound that has high light-emission efficiency, in particular little reduction in light-emission efficiency in a solid membrane, and is capable of emitting a near-infrared light having excellent light resistance; and a light-emitting composition and a light-emitting film that contain said squarylium compound. This squarylium compound is characterized by having a structure indicated by general formula (1). ##STR00001##

The present invention relates to a medicament design pocket of ODC. Based on the crystal structure of human ODC, the binding site area of putrescine and PLP ligand on the ODC homodimer interface is the medicament pocket, which is used for screening or designing or modifying inhibitors of human ODC, or screening or designing or modifying inhibitors of non-human ODC, or screening or designing or modifying protein inhibitor highly homologous to the binding site of putrescine and pyridoxal phosphate on the interface of ODC homodimer. The invention also provides the structure of the inhibitor and its application thereof. The technical solutions in the invention provide reliable theoretical basis for the research and development of human ODC, the prevention, treatment and diagnosis of tumors and pathogenic microbial infections, and the research and development and preparation of medicaments for the treatment of tumors or pathogenic microbial infections.

The present invention relates to a medicament design pocket of ODC. Based on the crystal structure of human ODC, the binding site area of putrescine and PLP ligand on the ODC homodimer interface is the medicament pocket, which is used for screening or designing or modifying inhibitors of human ODC, or screening or designing or modifying inhibitors of non-human ODC, or screening or designing or modifying protein inhibitor highly homologous to the binding site of putrescine and pyridoxal phosphate on the interface of ODC homodimer. The invention also provides the structure of the inhibitor and its application thereof. The technical solutions in the invention provide reliable theoretical basis for the research and development of human ODC, the prevention, treatment and diagnosis of tumors and pathogenic microbial infections, and the research and development and preparation of medicaments for the treatment of tumors or pathogenic microbial infections.

The present invention relates to a compound for an organic optoelectronic element, represented by chemical formula I, an organic optoelectronic element employing the same, and a display device. The details of chemical formula I above are defined as in the specification.

The present invention relates to a compound for an organic optoelectronic element, represented by chemical formula I, an organic optoelectronic element employing the same, and a display device. The details of chemical formula I above are defined as in the specification.

Disclosed are compounds of Formula (I)

##STR00001##

wherein: the two dotted lines represent either two single or two double bonds; Q is:

##STR00002##

R.sub.1 is F, Cl, —CN, or —CH.sub.3; R.sub.2 is Cl or —CH.sub.3; R.sub.3 is —C(CH.sub.3).sub.2OH or —CH.sub.2CH.sub.2OH; R.sub.a is H or —CH.sub.3; each R.sub.b is independently F, Cl, —CH.sub.3, and/or —OCH.sub.3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Disclosed are compounds of Formula (I)

##STR00001##

wherein: the two dotted lines represent either two single or two double bonds; Q is:

##STR00002##

R.sub.1 is F, Cl, —CN, or —CH.sub.3; R.sub.2 is Cl or —CH.sub.3; R.sub.3 is —C(CH.sub.3).sub.2OH or —CH.sub.2CH.sub.2OH; R.sub.a is H or —CH.sub.3; each R.sub.b is independently F, Cl, —CH.sub.3, and/or —OCH.sub.3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.